Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
Support MFO
Donate through PayPal
Biogen In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval
I think it is worth considering. 1) it is only back to levels before original trial looked dead. 2) Data is impressive with 20 to 40% decrease in declines in test scores and clinical outcomes. Both the low and high dose apparently reduced plaque. While it is not curative if it reduces decline safely FDA will be hard pressed not to approve, although PResident Warren may try to stop paying for it
Comments